Recursion Pharmaceuticals jumped by 16.44 percent on Wednesday to close at $6.09 apiece as investors repositioned portfolios ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback